BidaskClub downgraded shares of Illumina (NASDAQ:ILMN) from a buy rating to a hold rating in a report released on Tuesday, October 16th.
Several other research analysts also recently commented on the company. Deutsche Bank boosted their target price on Illumina to $350.00 and gave the stock a buy rating in a report on Friday, October 12th. ValuEngine downgraded Illumina from a strong-buy rating to a buy rating in a report on Thursday, October 11th. UBS Group assumed coverage on Illumina in a report on Tuesday, October 9th. They issued a neutral rating and a $340.00 target price on the stock. Piper Jaffray Companies boosted their target price on Illumina to $380.00 and gave the stock an overweight rating in a report on Tuesday, October 2nd. Finally, Cowen upped their price objective on Illumina from $315.00 to $400.00 and gave the stock a positive rating in a report on Thursday, September 6th. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock has an average rating of Buy and an average target price of $330.94.
Shares of ILMN traded down $10.30 on Tuesday, hitting $329.25. The company’s stock had a trading volume of 1,192,397 shares, compared to its average volume of 1,375,548. The company has a market capitalization of $50.37 billion, a P/E ratio of 82.31, a PEG ratio of 2.54 and a beta of 1.07. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.46 and a quick ratio of 2.24. Illumina has a fifty-two week low of $203.83 and a fifty-two week high of $372.61.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.26 by $0.26. The business had revenue of $853.00 million for the quarter, compared to the consensus estimate of $825.65 million. Illumina had a return on equity of 27.10% and a net margin of 21.09%. Illumina’s revenue was up 19.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.11 EPS. On average, sell-side analysts anticipate that Illumina will post 5.75 EPS for the current fiscal year.
In related news, SVP Oene Mark Van sold 1,091 shares of the company’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $354.18, for a total value of $386,410.38. Following the completion of the sale, the senior vice president now owns 11,126 shares in the company, valued at approximately $3,940,606.68. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Francis A. Desouza sold 2,100 shares of the company’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $353.66, for a total transaction of $742,686.00. Following the completion of the sale, the insider now owns 75,235 shares of the company’s stock, valued at approximately $26,607,610.10. The disclosure for this sale can be found here. Insiders have sold a total of 53,464 shares of company stock valued at $17,883,331 in the last quarter. Corporate insiders own 0.54% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ILMN. Janney Montgomery Scott LLC increased its holdings in Illumina by 10.0% during the 2nd quarter. Janney Montgomery Scott LLC now owns 23,555 shares of the life sciences company’s stock worth $6,579,000 after purchasing an additional 2,141 shares in the last quarter. Standard Life Aberdeen plc increased its holdings in Illumina by 31.1% during the 2nd quarter. Standard Life Aberdeen plc now owns 34,546 shares of the life sciences company’s stock worth $9,650,000 after purchasing an additional 8,199 shares in the last quarter. Waters Parkerson & CO. LLC bought a new position in Illumina during the 2nd quarter worth about $223,000. Bank of Nova Scotia increased its holdings in Illumina by 216.4% during the 2nd quarter. Bank of Nova Scotia now owns 59,185 shares of the life sciences company’s stock worth $16,529,000 after purchasing an additional 40,478 shares in the last quarter. Finally, Eqis Capital Management Inc. increased its holdings in Illumina by 40.7% during the 2nd quarter. Eqis Capital Management Inc. now owns 9,676 shares of the life sciences company’s stock worth $2,702,000 after purchasing an additional 2,797 shares in the last quarter. Institutional investors and hedge funds own 89.90% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.